Form 4: Corcept Director Gifts 28,000 Shares Under 10b5-1 Plan

Corcept Therapeutics Director James N. Wilson reported a planned gift of 28,000 common shares effective March 13, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Director James N. Wilson of Corcept Therapeutics Inc. (CORT) reported a disposition of 28,000 shares of common stock.
• The transaction is a gift (Transaction Code G) with a price of $0.00 per share.
• The effective transaction date is March 13, 2026.
• This transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following this transaction, James N. Wilson will beneficially own 1,106,532 shares indirectly through the James N. Wilson and Pamela D. Wilson Trust, 901,067 shares indirectly through James and Pamela Wilson Family Partners, 200,000 shares indirectly through the James N. Wilson 2025 Grantor Retained Annuity Trust, and 200,000 shares indirectly through the Pamela D. Wilson 2025 Grantor Retained Annuity Trust.
• Wilson disclaims beneficial ownership of shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners, except to the extent of his pecuniary interest, while retaining voting power.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it represents a disposition of shares by a director, it is a gift rather than a sale for cash, and it is pre-planned under a 10b5-1 plan, suggesting it is not driven by new material information.

Positives

• The transaction is a gift, not a sale for cash, which can be viewed as a neutral to slightly positive signal regarding the insider's long-term commitment to the company, as it is often for estate planning rather than a lack of confidence.
• The transaction is pre-planned under a Rule 10b5-1 plan, indicating it is not based on immediate, non-public information.

Negatives

• The director is reducing direct beneficial ownership, albeit through a gift.

Industry Context

StockSavvy.ai notes that insider gift transactions, especially those executed under a Rule 10b5-1 plan, are common for estate planning purposes among executives and directors. They typically do not reflect a change in the company's operational performance or strategic direction, nor do they directly relate to broader industry trends.

Related Party Transactions

• The gift of shares to various trusts and family partners constitutes related party transactions, as these entities are associated with the reporting person, James N. Wilson.

Stakeholder Impact

• Shareholders: Minimal direct impact. The number of shares gifted is a small fraction of the director's total beneficial ownership and the company's outstanding shares.
• Management/Employees: No direct impact.
• Creditors/Suppliers/Customers: No direct impact.

Key Dates

Recommendation

This Form 4 reports a routine insider gift transaction under a 10b5-1 plan, which is typically not indicative of fundamental changes in the company's prospects or valuation. It does not provide sufficient new information to alter an investment thesis, thus a 'hold' recommendation is appropriate for existing positions, and it offers no strong signal for new investment decisions.

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Transaction, James N. Wilson, Director, Stock Gift, 10b5-1 Plan, Beneficial Ownership